

# TABLE OF CONTENTS

April 19, 2010

No. 2185

## BUSINESS

- 1 Ajinomoto Pharm. to Enter Southeast Asian Market
- 2 Daiichi Sankyo Aims at 2nd Place in ARB Market in FY2012
- 2 Mochida to Boost Sales to ¥89.0 Bil. in FY2012
- 3 Hisamitsu: Profits Down Following Acquisition of Noven Pharma
- 3 Kyowa Kirin Ranked No. 5 in Development of Antibody Drugs: CEO Matsuda
- 4 Mr Chofuku Urges Makers to Explain Meaning of New Premium to Med. Institutions
- 4 Remicade Ranked No. 1 on HP Market
- 6 Taizhou City Invites Japanese Pharmas to Invest - Drug Market in China to Continue to Grow Despite Pressure on Prices
- 6 **BUSINESS NEWS IN BRIEF**
  - Nippon Shinyaku Licenses Once-Daily Tramadol from Labopharm
  - Zeria Licenses Hemostatic, Wound Dressing Agents from HemCon
  - Bayer Integrates Intendis
  - CMIC Completes Acquisition of Daiichi Sankyo Propharma's Shizuoka Plant
  - Alfresa to Tie Up with 4 Wholesalers
  - MCI Provides Tablet PCs to All MRs from Benesis
  - 637 Monitors Certified in 2nd JCROA Monitor Certification Test

## GENERICIS

- 8 Taiyo Can No Longer Be Family-Owned Company: President Aratani
- 8 **Survey**
  - HPs Have Stronger Resistance to Generics than GPs
- 9 **Commentary**
  - Taiyo Needs to Restart from Scratch
- 10 *Koroshō* to Prepare New GLs for BE Testing for Generics
- 10 Dispensing Pharmacies' Total Sales Will Continue to Decrease: JPA's Mr Iwatsuki

## REGULATORY

- 12 Daiichi Sankyo Applies for Edoxaban in Japan
- 12 Medway Data Falsification Was Organized: Committee Report
- 13 Gov't Considers Health/Nursing Care, Drugs as Growth Drivers: Mr Nagatsuma
- 13 Cautious Discussions Necessary on Lifting of Ban on *Kongo Shinryo*: Mr Nagatsuma
- 14 **REGULATORY NEWS IN BRIEF**
  - Arixtra Applied for Treatment of Acute DVT, PE: GSK
  - Fulvestrant Approved at 500 mg in EU: AZ
  - Afinitor, Temodal Transiently Excluded from DPC Payment System
  - Requirements for Med Institutions Conducting Regenerative Medicine Notified
  - Q&A on Biosimilars Issued

## TOPICS

- Takeda to Enhance Training of Executives with Global Business Capabilities

## R&D

- 16 Gefitinib Effective for EGFR-Positive NSCLC in First-Line Therapy
  - Gefitinib Also More Effective Than Cisplatin + Docetaxel
- 17 **R&D NEWS IN BRIEF**
  - Takeda Initiates Overseas PIII Trial of SGN-35 for Lymphoma
  - AnGes MG to Codevelop NF- $\kappa$ B Decoy with Shionogi
  - Sutent Extends OS in Japanese mRCC Patients in PII
  - Avastin + Standard Chemotherapy Significantly Extend PFS in NSCLC
  - Erbitux + Irinotecan Effective for KRAS Wild-Type CRC
  - 48% Fewer Deaths with Ticagrelor than Clopidogrel
  - Valsartan Delays Progression to Type 2 Diabetes in CV Patients with IGT

## SELF-MEDICATION

- 18 **SELF-MEDICATION NEWS IN BRIEF**
  - *Koroshō* to Encourage Switching of Ethical Drugs to OTC Status: Mr Nagatsuma
  - JACDS Calls For Continued Discussions on Online Sale of Drugs
  - JPA Supports Court Decision on Online Sale of Drugs: VP Idei

## MEDICAL DEVICES

- 19 **MEDICAL DEVICE NEWS IN BRIEF**
  - RDKK Launches Elecsys Reagent for RA
  - Kobayashi Pharm. Spins Off Medical Device Division
  - Medwatcher Japan Presents Petition on Use of Unapproved Medical Devices
- 19 **ON THE MOVE**
  - David Powell Appointed as AMDD Chairman

## OPINION

- More than Just the Money: Philip Carrigan

## MEDICAL FACILITIES & NURSING CARE

- 22 JSIM Introduces COI Self-Reporting Requirement from April 12
- 22 GSK to Disclose Payments to Physicians Made in 2009 and Onward
- 23 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
  - Norvasc, Lipitor Most Often Co-prescribed But in Only 4.3% of Patients
  - DB on Medicinal Plants Posted on NIBIO Website